2,840 reports of this reaction
5.6% of all AZACITIDINE reports
#2 most reported adverse reaction
FEBRILE NEUTROPENIA is the #2 most commonly reported adverse reaction for AZACITIDINE, manufactured by Celgene Corporation. There are 2,840 FDA adverse event reports linking AZACITIDINE to FEBRILE NEUTROPENIA. This represents approximately 5.6% of all 50,397 adverse event reports for this drug.
Patients taking AZACITIDINE who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is moderately reported among AZACITIDINE users, representing a notable but not dominant share of adverse events.
In addition to febrile neutropenia, the following adverse reactions have been reported for AZACITIDINE:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 2,840 FDA reports for AZACITIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 5.6% of all adverse event reports for AZACITIDINE, making it one of the most commonly reported side effect.
If you experience febrile neutropenia while taking AZACITIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.